Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that a large number of data presentations sponsored by the companies on ELIQUIS® (apixaban) and the treatment of atrial fibrillation will be presented at the American Heart Association 2012 Scientific Sessions, November 3-7, 2012, in Los Angeles, California. Among the presentations are two prespecified subanalyses from the ARISTOTLE trial: a more detailed analysis of ISTH major bleeding with ELIQUIS versus warfarin and an evaluation of the safety and efficacy of ELIQUIS versus warfarin in patients with prior warfarin experience (warfarin-experienced compared with warfarin-naïve). Also being presented is a subanalysis from ARISTOTLE of the safety and efficacy of ELIQUIS versus warfarin in patients with prior coronary artery disease. The ARISTOTLE trial evaluated the efficacy and safety of ELIQUIS, an investigational compound for the prevention of stroke or systemic embolism, in patients with nonvalvular atrial fibrillation compared with warfarin.
Company-sponsored real-world data analyses providing relevant insights on management of atrial fibrillation and experience with warfarin, such as the correlation between bleeding and discontinuation, warfarin outcomes in the real-world compared to trial data, and early ischemic outcomes after warfarin initiation will also be presented.
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions